Interim analysisIn clinical trials and other scientific studies, an interim analysis is an analysis of the current data from an ongoing trial, in which the primary research question is addressed. It has the potential to modify the conduct of the study. Depending on the results, an interim analysis may lead to(...)
Intermediate endpointIn clinical trials, intermediate endpoints are measures that may be associated with disease status or progression toward a primary endpoint (such as mortality or morbidity). It may be a measure of a body function or disease symptoms (e.g. measures of lung function in chronic obstructive(...)
Internal ValidityInternal validity in a clinical trial is the ability of the trial to reach the correct conclusion about whether or not, and to what extent, a treatment is causing a measured effect on the participants. It implies accurate and unbiased measurement of that effect.Internal validity is achieved(...)
International Council for HarmonisationFormerly the International Conference on Harmonisation. The International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) produces harmonised guidelines for global pharmaceutical development, and their regulation. It brings together the regulatory(...)
ICHFormerly the International Conference on Harmonisation. The International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) produces harmonised guidelines for global pharmaceutical development, and their regulation. It brings together the regulatory(...)
INAHTAInternational Network of Agencies for Health Technology Assessment http://www.inahta.org/"
International Non-proprietary NameAn International Non-proprietary Name (INN) is an official generic name given to a pharmaceutical compound. INNs facilitate communication by providing a standard name for each substance in the market with more than one brand name. Each INN is a unique name that is globally recognised and is(...)
